nyx-783
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 25, 2019 (NCT04044664)
Timeline
Indications
Mechanism of action
GRIN2B activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05447286 | Phase 1 | Jan 31, 2023 | Aptinyx, National Institute on Drug Abuse (NIDA), Yale University |
| NCT05181995 | Phase 2/Phase 3 (Phase 3) | Dec 13, 2021 | Aptinyx, Worldwide Clinical Trials |
| NCT04044664 | Phase 2 | Jan 25, 2019 | Aptinyx, Harvard University, Premier Research Group |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptinyx | For profit | 3 | 2 | 3 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2023 |
| Premier Research Group | For profit | 1 | 0 | 1 | 2019 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1